Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 2, 2018
The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting CellsChristian Merz, Jaromir Sykora, Viola Marschall, et al.
Oncotarget|February 25, 2016
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesisAnna Raimbault, Cecile Pierre-Eugene, Alexandra Rouquette, et al.
Rheumatology (Oxford, England)|February 27, 2010
Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg-Strauss syndromeStefan Wieczorek, Julia U Holle, Jan P Bremer, et al.
Molecular Cancer Therapeutics|October 9, 2013
APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptorsChristian Gieffers, Michael Kluge, Christian Merz, et al.
Frontiers in Oncology|October 10, 2018
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor ImmunityMeinolf Thiemann, David M Richards, Karl Heinonen, et al.
Journal for Immunotherapy of Cancer|July 21, 2019
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionalityDavid M Richards, Viola Marschall, Katharina Billian-Frey, et al.
Leukemia Research|March 18, 2018
Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDSTobias Boch, Thomas Luft, Georgia Metzgeroth, et al.
Cell Death & Disease|April 20, 2018
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cellsKaren Legler, Charlotte Hauser, Jan-Hendrik Egberts, et al.
Eclinicalmedicine|November 8, 2024
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialMaria Pilar Ruiz Seco, José Ramón Paño Pardo, Christian Schoergenhofer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2014
A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastomaWolfgang Wick, Harald Fricke, Klaus Junge, et al.
Pageof 4